![]() |
市场调查报告书
商品编码
1348457
旋塞阀的全球市场:规模,占有率,趋势分析(2024年~2030年):MedCoreStopcock Market Size, Share & Trends Analysis | Global | 2024-2030 | MedCore |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
2023年,全球旋塞阀市场规模达1.751亿美元,较2022年的1.657亿美元成长5.7%。展望未来,预计复合年增长率 (CAGR) 为 4.9%,最终达到 2.455 亿美元。目前,全球旋塞阀市场由碧迪公司(BD)和贝朗公司主导。
旋塞阀正面临来自新兴无针连接器的竞争,这些连接器已被公认为市场上的替代技术。无针连接器具有多种优点,包括改善感染控制、减少液体浪费以及提高液体管理的准确性。这些连接器变得越来越熟悉和采用,影响了传统的旋塞阀细分市场。随着无针连接器的日益普及,它们正在某些应用和医疗保健环境中取代传统的旋塞阀。
2023年,碧迪公司(BD)成为全球旋塞阀市场无可争议的领导者,巩固了其在产业中的主导地位。BD 提供两种重要产品。BD压倒性的影响力不仅延伸至市占率排名第二的北美和西欧,也延伸至全球许多区域市场。
同年,贝朗确立了世界旋塞阀领域第二大影响力竞争者的地位。着名的输液帮浦製造专家贝朗公司采取了独特的方法,将旋塞阀装置与其他医疗设备捆绑在一起。许多医院喜欢综合采购方式,并选择从单一製造商采购大部分输液产品。这项战略优势显着增强了贝朗在旋塞阀市场的地位,特别是在西欧,贝朗在各种医疗设备领域始终表现出色。
本报告提供全球旋塞阀市场相关调查,提供市场概要,以及各市场区隔,各地区趋势,竞争情形等资讯。
In 2023, the worldwide stopcock market achieved a total valuation of $175.1 million, reflecting a 5.7% increase compared to the $165.7 million recorded in 2022. Projections for the upcoming period suggest a sustained growth trajectory, with a compound annual growth rate (CAGR) of 4.9%, ultimately reaching $245.5 million. Presently, the global stopcock market is under the dominance of Becton Dickinson (BD) and B. Braun.
Our comprehensive medical market research involved a thorough analysis of more than 20 stopcock companies across seven continents. Employing a rigorous methodology, we delved into market sizes, unit sales, company market shares, and generated precise forecasts.
Stopcocks are encountering competition from emerging needleless connectors, which are gaining recognition as alternative technologies in the market. Needleless connectors offer various advantages, such as improved infection control, reduced fluid wastage, and enhanced precision in fluid management. These connectors are increasingly becoming more accessible and adopted, influencing traditional segments of the stopcock market. As needleless connectors continue to gain popularity, they are gradually displacing conventional stopcocks in specific applications and healthcare settings.
In 2023, Becton Dickinson (BD) emerged as the undisputed leader in the global stopcock market, solidifying its dominant position in the industry. BD proudly offers two significant offerings: the Alaris® lipid-resistant, 3-way stopcock, and an alternative latex- and PVC-free version of this essential medical device. BD's commanding influence extends not only to North America and Western Europe, where it holds the second-largest market share, but also to numerous regional markets across the globe.
During the same year, B. Braun secured its position as the second most influential competitor in the global stopcock arena. Renowned for its expertise in infusion pump manufacturing, B. Braun adopts a distinctive approach by bundling its stopcock devices with other medical equipment. Many hospitals prefer a comprehensive sourcing approach, choosing to procure the majority of their infusion products from a single manufacturer. This strategic advantage significantly enhances B. Braun's standing in the stopcock market, particularly in Western Europe, where it consistently excels across a diverse range of medical devices.
The lower tiers of the global stopcock market landscape are predominantly occupied by smaller, localized competitors. These agile players specialize in producing straightforward, cost-effective products tailored for hospital use. Nevertheless, their market share remains modest compared to industry giants capable of bundling stopcock sales with a comprehensive suite of infusion therapy products. Notably, companies like B. Braun and Becton Dickinson, among others, reign supreme in this category, leveraging their extensive product portfolios to maintain a dominant presence.